CASP3 and neoplasm: Six to seven hours after SONALA-001 infusion (10 mg/kg), patients received MRgFUS with the Exablate 4000 Type 2.0 (220 kHz) device to one-half of their tumor volume, with cohorts of increasing energy of 200 J, 400 J, and 800 J. Four days after SDT treatment, the tumor was resected, and the SDT-treated and control halves of each tumor were compared for biomarkers of lipoperoxidation through 4-hydroxynonenal (4HNE) and for apoptosis via detection of cleaved caspase-3 (ClCas3) [27].